Unlocking the Mysteries of CTNNB1 Syndrome: A Modern Era of Rare Disease Research
Rare Disease Day serves as a crucial reminder of the challenges faced by individuals and families affected by conditions impacting a relatively small percentage of the population. Yet, collectively, rare diseases affect millions. Currently, nearly three million people in Spain are impacted. The Biofisika Institute (CSIC, EHU) is at the forefront of research into one such condition: CTNNB1 neurodevelopmental syndrome, a rare genetic disorder affecting brain development.
The Role of Beta-Catenin and the Impact of Mutations
CTNNB1 syndrome stems from mutations in the CTNNB1 gene, which provides instructions for making beta-catenin protein. Beta-catenin is a key player in cell adhesion and crucial for proper brain formation. Most mutations associated with the syndrome result in incomplete or misfolded proteins, disrupting these critical developmental processes.
Even though fewer than 50 cases have been diagnosed in Spain, understanding the molecular basis of this syndrome is paramount. Sonia Bañuelos, a researcher at the Biofisika Institute and lecturer at the University of the Basque Country (EHU), explains, “Our goal is to understand how these mutations prevent the brain from forming correctly. Understanding the mechanisms at the molecular level is essential so that specific therapies can be developed in the future.”
A Collaborative Approach to Complex Research
The research isn’t happening in isolation. Bañuelos leads a collaborative effort involving a neuropsychology team from the University of Deusto, molecular genetists from the Biobizkaia Institute at Cruces University Hospital, and the brain organoid platform at the Achucarro Neuroscience Center. The Spanish Association of CTNNB1 Patients, based in Bizkaia, is also actively involved.
Leveraging Cutting-Edge Technologies
The Biofisika Institute team is employing a sophisticated toolkit to unravel the complexities of CTNNB1 syndrome. They utilize tools based on the three-dimensional structure of proteins to predict how mutations affect the interaction between beta-catenin and cadherin, essential components of cell adhesion complexes. These predictions are then rigorously tested using biophysical techniques.
To validate their findings, the team produces mutated versions of the protein corresponding to real cases identified within the Spanish cohort in bacteria. Brain organoids – miniature, simplified versions of the human brain grown in the lab – are used to model how these alterations impact nervous tissue development more accurately.
Future Trends: From Basic Research to Rational Drug Design
While currently focused on basic research, the team believes their function could pave the way for “rational designed therapies.” This approach involves developing treatments specifically targeted at correcting the underlying molecular defects caused by the mutations. Recent research, published in October 2025, details how inducing translational readthrough with aminoglycosides and protein synthesis stimulators, or inhibiting beta-catenin degradation with MG-132, showed partial rescue of beta-catenin transcriptional activity in some variants.
The use of brain organoids is expected to become increasingly prevalent in rare disease research, offering a more physiologically relevant model for studying disease mechanisms and testing potential therapies than traditional cell cultures. Advances in computational modeling and artificial intelligence will also play a crucial role in predicting the impact of genetic variations and identifying potential drug targets.
Did you know? CTNNB1 syndrome often presents with a range of symptoms, including microcephaly, motor impairment, sight problems, sleep disturbances, and symptoms of autism spectrum disorder (ASD).
The Importance of Investing in Rare Disease Research
Bañuelos emphasizes the critical need for continued investment in rare disease research: “Understanding the mechanisms of a disease is the first step towards finding a cure. That is why research on rare diseases is necessary.” This sentiment underscores the broader importance of supporting research into conditions that, while individually rare, collectively impact a significant portion of the population.
Frequently Asked Questions (FAQ)
Q: What causes CTNNB1 syndrome?
A: CTNNB1 syndrome is caused by genetic mutations in the CTNNB1 gene, which affects the production of beta-catenin protein.
Q: What are the common symptoms of CTNNB1 syndrome?
A: Common symptoms include microcephaly, motor impairment, sight problems, sleep disturbances, and symptoms of autism spectrum disorder.
Q: Is there a cure for CTNNB1 syndrome?
A: Currently, there is no cure, but research is ongoing to develop targeted therapies.
Q: How are researchers studying CTNNB1 syndrome?
A: Researchers are using techniques like protein structure prediction, biophysical analysis, and brain organoids to understand the disease mechanisms.
Pro Tip: Early stimulation and intervention are crucial for individuals with CTNNB1 syndrome, as early attainment of developmental milestones is linked to better clinical outcomes.
Learn more about CTNNB1 syndrome and support research efforts at the CTNNB1 Foundation.
Have you or a loved one been affected by a rare disease? Share your story in the comments below.
